These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 18231580)

  • 41. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial.
    Peduzzi E; Westerfeld N; Zurbriggen R; Pluschke G; Daubenberger CA
    Clin Immunol; 2008 May; 127(2):188-97. PubMed ID: 18337175
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity of the Plasmodium falciparum asexual blood-stage synthetic peptide vaccine SPf66.
    Millet P; Campbell GH; Sulzer AJ; Grady KK; Pohl J; Aikawa M; Collins WE
    Am J Trop Med Hyg; 1993 Mar; 48(3):424-31. PubMed ID: 7682382
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaccine efficacy of recombinant Plasmodium falciparum merozoite surface protein 1 in malaria-naive, -exposed, and/or -rechallenged Aotus vociferans monkeys.
    Egan AF; Blackman MJ; Kaslow DC
    Infect Immun; 2000 Mar; 68(3):1418-27. PubMed ID: 10678955
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint.
    Porter MD; Nicki J; Pool CD; DeBot M; Illam RM; Brando C; Bozick B; De La Vega P; Angra D; Spaccapelo R; Crisanti A; Murphy JR; Bennett JW; Schwenk RJ; Ockenhouse CF; Dutta S
    Clin Vaccine Immunol; 2013 Jun; 20(6):803-10. PubMed ID: 23536694
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens.
    Campo JJ; Dobaño C; Sacarlal J; Guinovart C; Mayor A; Angov E; Dutta S; Chitnis C; Macete E; Aponte JJ; Alonso PL
    PLoS One; 2011; 6(10):e25779. PubMed ID: 22022448
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses.
    Powell TJ; Tang J; Derome ME; Mitchell RA; Jacobs A; Deng Y; Palath N; Cardenas E; Boyd JG; Nardin E
    Vaccine; 2013 Apr; 31(15):1898-904. PubMed ID: 23481177
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites.
    Egan JE; Hoffman SL; Haynes JD; Sadoff JC; Schneider I; Grau GE; Hollingdale MR; Ballou WR; Gordon DM
    Am J Trop Med Hyg; 1993 Aug; 49(2):166-73. PubMed ID: 8357078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.
    Lusingu JP; Gesase S; Msham S; Francis F; Lemnge M; Seth M; Sembuche S; Rutta A; Minja D; Segeja MD; Bosomprah S; Cousens S; Noor R; Chilengi R; Druilhe P
    Malar J; 2009 Jul; 8():163. PubMed ID: 19607731
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.
    Malkin EM; Diemert DJ; McArthur JH; Perreault JR; Miles AP; Giersing BK; Mullen GE; Orcutt A; Muratova O; Awkal M; Zhou H; Wang J; Stowers A; Long CA; Mahanty S; Miller LH; Saul A; Durbin AP
    Infect Immun; 2005 Jun; 73(6):3677-85. PubMed ID: 15908397
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite Protein.
    Speake C; Pichugin A; Sahu T; Malkov V; Morrison R; Pei Y; Juompan L; Milman N; Zarling S; Anderson C; Wong-Madden S; Wendler J; Ishizuka A; MacMillen ZW; Garcia V; Kappe SH; Krzych U; Duffy PE
    PLoS One; 2016; 11(7):e0159449. PubMed ID: 27434123
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of novel vaccination regimens using viral vectored liver stage malaria vaccines encoding ME-TRAP.
    Bliss CM; Bowyer G; Anagnostou NA; Havelock T; Snudden CM; Davies H; de Cassan SC; Grobbelaar A; Lawrie AM; Venkatraman N; Poulton ID; Roberts R; Mange PB; Choudhary P; Faust SN; Colloca S; Gilbert SC; Nicosia A; Hill AVS; Ewer KJ
    Sci Rep; 2018 Feb; 8(1):3390. PubMed ID: 29467399
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of the pre-erythrocytic candidate malaria vaccine RTS,S/AS01E on blood stage immunity in young children.
    Bejon P; Cook J; Bergmann-Leitner E; Olotu A; Lusingu J; Mwacharo J; Vekemans J; Njuguna P; Leach A; Lievens M; Dutta S; von Seidlein L; Savarese B; Villafana T; Lemnge MM; Cohen J; Marsh K; Corran PH; Angov E; Riley EM; Drakeley CJ
    J Infect Dis; 2011 Jul; 204(1):9-18. PubMed ID: 21628653
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of a Plasmodium falciparum sporozoite vaccine: boosting of antibody response in a population with prior natural exposure to malaria.
    Sherwood JA; Oster CN; Adoyo-Adoyo M; Beier JC; Gachihi GS; Nyakundi PM; Ballou WR; Brandling-Bennett AD; Schwartz IK; Were JB
    Trans R Soc Trop Med Hyg; 1991; 85(3):336-40. PubMed ID: 1949134
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175.
    Chitnis CE; Mukherjee P; Mehta S; Yazdani SS; Dhawan S; Shakri AR; Bhardwaj R; Gupta PK; Hans D; Mazumdar S; Singh B; Kumar S; Pandey G; Parulekar V; Imbault N; Shivyogi P; Godbole G; Mohan K; Leroy O; Singh K; Chauhan VS
    PLoS One; 2015; 10(4):e0117820. PubMed ID: 25927360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge.
    Calvo-Calle JM; Oliveira GA; Watta CO; Soverow J; Parra-Lopez C; Nardin EH
    Infect Immun; 2006 Dec; 74(12):6929-39. PubMed ID: 17030584
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Down-selecting circumsporozoite protein-based malaria vaccine: A comparison of malaria sporozoite challenge model.
    Amelia F; Iyori M; Emran TB; Yamamoto DS; Genshi K; Otsuka H; Onoue Y; Yusuf Y; Islam A; Yoshida S
    Parasite Immunol; 2019 May; 41(5):e12624. PubMed ID: 30883819
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Modest heterologous protection after Plasmodium falciparum sporozoite immunization: a double-blind randomized controlled clinical trial.
    Walk J; Reuling IJ; Behet MC; Meerstein-Kessel L; Graumans W; van Gemert GJ; Siebelink-Stoter R; van de Vegte-Bolmer M; Janssen T; Teelen K; de Wilt JHW; de Mast Q; van der Ven AJ; Diez Benavente E; Campino S; Clark TG; Huynen MA; Hermsen CC; Bijker EM; Scholzen A; Sauerwein RW
    BMC Med; 2017 Sep; 15(1):168. PubMed ID: 28903777
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine.
    Kaba SA; McCoy ME; Doll TA; Brando C; Guo Q; Dasgupta D; Yang Y; Mittelholzer C; Spaccapelo R; Crisanti A; Burkhard P; Lanar DE
    PLoS One; 2012; 7(10):e48304. PubMed ID: 23144750
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy model for antibody-mediated pre-erythrocytic malaria vaccines.
    White MT; Griffin JT; Riley EM; Drakeley CJ; Moorman AM; Sumba PO; Kazura JW; Ghani AC; John CC
    Proc Biol Sci; 2011 May; 278(1710):1298-305. PubMed ID: 20943696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.